Immunovant, Inc. Profile Avatar - Palmy Investing

Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fra…
Biotechnology
US, New York [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

Searching for a Dividend Aristocrat? Sign Up to view the entire dividend history of Immunovant, Inc.

Growth Rates
0.00% YoY
0.00% 3Yr
0.00% 5Yr
0.00% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
- -% Yield
0.00% Payout Ratio
End of IMVT's Analysis
CIK: 1764013 CUSIP: 45258J102 ISIN: US45258J1025 LEI: - UEI: -
Secondary Listings
IMVT has no secondary listings inside our databases.